Armata Pharmaceuticals Inc. (NYSE:ARMP) stock is trading higher on Monday after the company announced significant clinical, regulatory, manufacturing, and operational progress supporting the advancement of its lead therapeutic candidate, AP-SA02.

The late clinical-stage biotechnology business is moving the intravenously administered Staphylococcus aureus multi-phage product toward a pivotal Phase 3 superiority study set to begin in the second half of 2026.

The upcoming trial is designed to support a future Biologics License Application for the treatment of complicated bacteremia caused by methicillin-sensitive (MSSA) or methicillin-resistant (MRSA) strains.

Regulatory Alignment And Operational Readiness

Armata said it submitted the complete Phase 3 protocol to the U.S. Food and Drug Administration. The filing also included responses to all feedback from the agency’s End-of-Phase 2 meeting.

These submissions resolved inquiries across clinical, regulatory, and chemistry, manufacturing, and controls parameters.

Operationally, the company concluded four engineering runs for the candidate at its in-house cGMP facility located in Los Angeles, California.

Manufacturing clinical trial material at this facility serves as the next planned step to prepare for late-stage clinical evaluation.

Clinical Background And Government Backing

AP-SA02 is being developed as an adjunct treatment combined with best available antibiotic therapy.

The multi-phage cocktail has earned Qualified Infectious Disease Product and Fast Track designations from regulatory authorities.

Armata previously reported positive safety, tolerability and efficacy data from its Phase 1b/2a diSArm study. The company presented those results during a late-breaking oral session at IDWeek 2025.

To assist with trial readiness, the company secured a $2.5 million continuation award from the U.S. Department of Defense in June.

The milestone brings cumulative funding under the award to $28.7 million. Management continues active dialogue with defense officials regarding potential expanded support for trial execution while simultaneously assessing additional external funding pathways.

Executive Leadership Update

Armata also promoted David House to chief financial officer. He previously served as senior vice president of finance and principal financial officer since August 2024.

ARMP Stock Price Activity: Armata Pharmaceuticals shares were up 10.27% at $4.97 at the time of publication on Monday, according to Benzinga Pro data.

Image via Shutterstock